# High-Level Overview
Synthorx is a biotechnology company, not a technology company, though it employs cutting-edge synthetic biology technology. Founded in 2014 and headquartered in La Jolla, California, Synthorx develops cancer and autoimmune therapies using its proprietary Expanded Genetic Alphabet platform.[1][3] The company was acquired by pharmaceutical giant Sanofi in January 2020 for $2.5 billion, enhancing Sanofi's position in oncology and immunology.[3]
Synthorx solves a fundamental biological constraint: the natural genetic code contains only 64 codons encoding 20 amino acids. By expanding the genetic alphabet with synthetic base pairs (X and Y), Synthorx can encode up to 172 codons, enabling the creation of proteins with novel amino acids and enhanced therapeutic properties.[1] This capability allows the company to design Synthorin cytokines—optimized protein therapeutics that selectively tune receptor pharmacology and extend half-life, improving efficacy while reducing safety liabilities.[4]
# Origin Story
Synthorx was founded in 2014 based on seminal discoveries by Floyd Romesberg, Ph.D., a professor at The Scripps Research Institute who had spent over 15 years developing synthetic bases.[1][2] Romesberg's breakthrough—creating stable synthetic DNA base pairs that could be replicated and maintained by living cells—provided the scientific foundation for the company's platform.[2]
The founding vision was ambitious: use expanded genetic code to dramatically increase the number of available codons, enabling the creation of proteins with new functionalities and diverse chemical properties.[1] Early validation came in August 2015 when Synthorx successfully produced full-length proteins containing novel amino acids using its semi-synthetic DNA template, demonstrating that the synthetic base pairs were compatible with natural cellular machinery.[2] This proof-of-concept attracted investors including Avalon Ventures and Correlation Ventures, and the company raised $79 million before its acquisition.[2][3]
# Core Differentiators
# Role in the Broader Tech Landscape
Synthorx operates at the intersection of synthetic biology and precision medicine, riding the wave of advances in genetic engineering and immunotherapy. The timing is critical: IL-2 has been studied for nearly 40 years and is recognized as potentially the most valuable molecule for boosting immuno-oncology efficacy, yet its clinical use has been limited by safety concerns.[4] Synthorx's ability to create optimized IL-2 variants addresses this unmet need precisely when checkpoint inhibitors, CAR-T therapies, and cancer vaccines are becoming standard-of-care treatments that could benefit from enhanced cytokine support.[4]
The company's acquisition by Sanofi signals broader industry recognition that synthetic biology platforms can unlock new therapeutic possibilities. By expanding the chemical and structural repertoire of protein therapeutics, Synthorx influences how the biotech ecosystem approaches protein drug design—moving beyond incremental modifications to fundamentally new protein architectures.[4]
# Quick Take & Future Outlook
Synthorx represents a rare convergence of foundational science and clinical application. Under Sanofi's ownership, the company has transitioned from proof-of-concept to clinical development, with THOR-707 advancing through trials. The key question is whether the expanded genetic alphabet platform can deliver superior clinical outcomes that justify its complexity and manufacturing requirements compared to conventional biologics.
Looking ahead, Synthorx's influence will depend on clinical trial success and the platform's scalability. If THOR-707 and THOR-809 demonstrate meaningful improvements in efficacy or safety, the platform could become a template for next-generation cytokine design and potentially expand into other protein therapeutic classes. Conversely, if manufacturing complexity or immunogenicity concerns emerge, the platform's impact may remain niche. Either way, Synthorx has already proven that synthetic biology can move beyond academic curiosity into practical medicine—a milestone that will shape how biotech approaches protein engineering for the next decade.
Synthorx has raised $73.0M in total across 2 funding rounds.
Synthorx's investors include Morgenthaler Ventures, OrbiMed, RA Capital, Samsara BioCapital, SR One.
Synthorx has raised $73.0M across 2 funding rounds. Most recently, it raised $63.0M Series C in April 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2018 | $63.0M Series C | Morgenthaler Ventures, OrbiMed, RA Capital, Samsara BioCapital, SR One | |
| Jul 1, 2016 | $10.0M Series B | RA Capital |
